ADPT Adaptive Biotechnologies Corporation
Debt Financing ·
Adaptive Biotechnologies priced $300 million of 0% convertible senior notes due 2031, upsized from $250 million. J. Wood Capital Advisors LLC, its financial advisor on the offering, agreed to purchase about $10 million of shares.
Adaptive Biotechnologies plans a $250 million offering of convertible senior notes due 2031 and expects to use up to $25 million of the proceeds to repurchase common stock. The interest rate and conversion terms will be set only at pricing.
Adaptive Biotechnologies Corporation uses sequencing and computational biology to read the adaptive immune system and develop clinical products. Its MRD business uses a highly sensitive next-generation sequencing assay to measure minimal residual disease in hematologic malignancies. The clonoSEQ clinical diagnostic test is offered to clinicians, and the clonoSEQ assay is offered to biopharmaceutical partners for drug development. clonoSEQ is the first test authorized by the FDA for detection and monitoring of MRD in multiple myeloma, B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Its Immune Medicine business offers immune receptor sequencing, licensing of its proprietary data, TCR-antigen prediction models and target discovery, with work in autoimmunity including multiple sclerosis and type 1 diabetes. In December 2025 the company entered into two non-exclusive agreements with Pfizer Inc. to leverage its TCR discovery platform in rheumatoid arthritis and broader immunology. In 2025 revenue was $277.0 million, compared with $179.0 million in 2024, and total MRD revenue was $212.3 million.
| Product or program | What it is | Stage |
|---|---|---|
| clonoSEQ clinical test | NGS assay measuring MRD in lymphoid cancers | FDA authorized for MM, B-ALL and CLL |
| clonoSEQ assay (MRD Pharma) | MRD assay offered to biopharmaceutical partners for drug development | |
| Immune Medicine platform | TCR and BCR sequencing, TCR-antigen prediction and target discovery |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $277.0 million | $179.0 million |
| Research and development | $93.8 million | $103.0 million |
| Net income (loss) | -$59.5 million | -$159.5 million |
| Cash from operations | -$46.0 million | -$95.2 million |
| Cash and equivalents | $70.5 million | $47.9 million |
| Short-term investments | $156.5 million | $174.4 million |
Our latest story on this, dated Jun 17, 2026: "Adaptive Biotechnologies prices upsized $300 million convertible notes". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 17, 2026: "Adaptive Biotechnologies prices upsized $300 million convertible notes". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 15, 2026: "Adaptive Biotechnologies plans $250 million of convertible notes". The story links the filing or release it is based on. Read the story.
Adaptive Biotechnologies Corporation trades under the ticker ADPT on NASDAQ.
Adaptive Biotechnologies Corporation is listed on NASDAQ. Our directory also records these other listings: GETTEX:1HM; LS:A2PLR5.
The SEC Central Index Key (CIK) for Adaptive Biotechnologies Corporation is 1478320. Its filings are on SEC EDGAR.
159,595,842 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04.
Our directory records Adaptive Biotechnologies Corporation under United States.
Our directory classifies Adaptive Biotechnologies Corporation as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Adaptive Biotechnologies Corporation is US00650F1093.
aibio.space lists Adaptive Biotechnologies Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as WA.
Adaptive Biotechnologies Corporation uses sequencing and computational biology to read the adaptive immune system and develop clinical products. Its MRD business uses a highly sensitive next-generation sequencing assay to measure minimal residual disease in hematologic malignancies.
clonoSEQ clinical test: NGS assay measuring MRD in lymphoid cancers Stage: FDA authorized for MM, B-ALL and CLL.
clonoSEQ assay (MRD Pharma): MRD assay offered to biopharmaceutical partners for drug development
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio